John Ballantyne

John Ballantyne is a founder of Agathos Biologics. He co-founded Aldevron with Michael Chambers in 1998 and has been the Chief Scientific Officer since its establishment. His innovative work at Aldevron includes creation of the GMP Source product line and collaborative research with military scientists in the development of vaccine and passive-based countermeasures to lethal and potentially weaponized viral hemorrhagic threats such as Ebola, Marburg and some hantavirus family members. He leads the research and development team at Aldevron which develops new methods and products through internal programs, collaborations, and technology licensing. John sees the advances in biotechnology providing opportunities for Agathos to enable ethical pharmaceutical development that will benefit patients, employees, and society. Ballantyne received undergraduate degrees in Pharmacy from the Central Institute of Technology and the University of Otago in New Zealand. After beginning graduate school in New Zealand he transferred to the United States in 1994 and completed his Ph.D. in Pharmaceutical Sciences at North Dakota State University.

John Ballantyne is the CSO & VP at Aldevron, based in United States, North America. With a background in Biotechnology, John Ballantyne has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.